๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
PepGen Inc. (PEPG)
NASDAQ: PEPG ยท Real-Time Price ยท USD
3.780
-0.150 (-3.82%)
At close: Nov 20, 2026, 4:00 PM EST
3.790
+0.010 (0.26%)
After-hours: Nov 20, 2026, 7:39 PM EST
โ† View all transcripts

Study result

Nov 10, 2026

Summary

Four 10 mg/kg doses produced 46.5% mean splicing correction and improvements across myotonia, grip strength, mobility and balance. Safety was favorable; 12.5 mg/kg results are expected in H1 2027, with longer-term OLE data planned for January 2027.

Operator

Welcome to the PepGen conference call to discuss positive top-line results from the 10 mg/kg MAD cohort in the phase II FREEDOM2- DM1 study. At this time, all participants are in a listen-only mode. Following management's prepared remarks, we will hold a Q&A session. To ensure that we have ample time to address everyone's questions, we would ask that each person limit themselves to one question and one follow-up. As a reminder, this call is being recorded today. I would now like to turn the conference call over to Laurence Watts of New Street Investor Relations. Please go ahead.

Laurence Watts
CEO and Founder, New Street Investor Relations

Thank you, operator. Joining us on the call today are PepGen's President and Chief Executive Officer, James McArthur, Chief Financial Officer, Noel Donnelly, Executive Vice President, Head of Research and Development, Dr. Paul Streck, and Dr. Johanna Hamel, Associate Professor of Neurology, Pathology, and Laboratory Medicine at the University of Rochester. In addition to this data, PepGen today released third quarter 2026 financial results and corporate highlights. Both press releases and this presentation are available on our investors page at pepgen.com. During this call, management will make forward-looking statements, including statements related to its phase II trial of PGN-EDODM1, as well as the timing of additional or future data from the studies and PepGen's development plans. Our actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of risks and uncertainties.

Factors that could cause these results to be different from these statements include factors PepGen describes in its security filings, including its annual report on Form 10-K and quarterly reports on Form 10-Q. PepGen undertakes no duty or obligation to update any forward-looking statements as a result of new information, future events, or changes in its expectations. With that, I will turn the call over to James McArthur, President and Chief Executive Officer of PepGen. James?

James McArthur
President and CEO, PepGen

Thank you, Laurence. Good morning, everyone. Thank you for joining us for today's call. As Laurence mentioned, we're joined today by Dr. Paul Streck, PepGen's Head of R&D, and Dr. Johanna Hamel of the University of Rochester, one of the principal investigators in our FREEDOM study. I'll provide a high-level summary of the data, followed by Dr. Streck, who will review the technology behind EDODM1 and review the trial design, the safety and splicing results. Dr. Hamel will follow and review the clinical functional endpoints and what these results could potentially mean for people living with DM1. Finally, we'll conclude with Q&A. We're very pleased to report the results from the 10 mg/kg PGN-EDODM1 FREEDOM2 clinical trial today. Along with the excellent splicing correction, we also observed improvement in multiple key functional measures, assessing myotonia, hand grip strength, mobility and balance, and ambulation.

In addition, PGN-EDODM1 continues to demonstrate a favorable safety profile. In short, these positive data strengthen our belief that PGN-EDODM1 has the potential, if approved, to set a new standard for the treatment of DM1. Four doses of PGN-EDODM1 at 10 mg/kg resulted in a 46.5% mean improvement in splicing correction, with four of six participants having more than 50% splicing correction. Based on publicly reported clinical data, this is the highest splicing correction reported to date in a multiple-dose DM1 study. Turning to functional measures, we observed a 4.3-second improvement in myotonia, as measured by video hand opening time at week 13, which was associated with splicing correction of CLCN1, a muscle chloride channel driving myotonia in DM1. We saw further functional benefit across both proximal and distal muscle groups impacted by DM1 in a dose-dependent manner.

At 10 mg/kg, we observed notable improvements in hand grip strength, timed up and go, and 10 m walk/run test, providing compelling evidence of PGN-EDODM1's potential to address multiple clinical manifestations of DM1. With respect to safety, PGN-EDODM1 at 10 mg/kg continues to present a favorable tolerability and safety profile, with no serious adverse events, adverse events of special interest, dose-limiting toxicities, or discontinuations. Importantly, we did not observe any cumulative increase in safety signals with multiple doses, and four adverse events related to kidney biomarkers were all mild. In summary, these positive data strengthen our belief that PGN-EDODM1 has the potential, if approved, to set a new standard for the treatment of DM1. I'll now hand over the presentation to my colleague, Dr. Paul Streck, Head of R&D, to take you through our clinical results in more detail.

Paul Streck
EVP and Head of Research and Development, PepGen

Thank you, James. Myotonic dystrophy type 1, or DM1, is a devastating rare genetic disease which increases in severity in each successive generation. It robs patients of critical function and ultimately shortens their lives. It affects 110,000 or more patients in the U.S. and E.U., and there are no approved therapies that address the underlying pathology of the disease. To remind everyone, DM1 is caused by expanded CTG repeats in the dystrophia myotonica protein kinase, or DMPK, gene. This results in toxic DMPK RNA that disrupts normal RNA splicing and drives the disease. PGN-EDODM1 is designed specifically to bind to the CUG repeat in the pathogenic DMPK RNA with the goal of restoring splicing. A key aspect of its design is the use of our enhanced delivery oligonucleotide, or EDO platform.

Our EDO technology uses an engineered peptide for receptor-independent oligonucleotide delivery and is designed to support broad tissue delivery, which is believed to be critically important given the multisystemic nature of this condition. Once inside the cell, our EDO technology promotes endosomal escape and delivery of the therapeutic oligonucleotide into the nucleus. In DM1 cells in vitro, PGN-EDODM1 demonstrates up to a 98-fold increase in nuclear uptake compared with naked oligonucleotide. Nuclear delivery is critical because the pathogenic DMPK RNA that drives the underlying disease of DM1 resides in the nucleus. Unlike many other approaches in the clinic that indiscriminately degrade normal and pathogenic DMPK RNA, the PGN-EDODM1 oligonucleotide is designed to bind selectively to the expanded CUG repeats in the pathogenic DMPK transcript. This is designed to disrupt the stem-loop structure of this pathogenic RNA without degrading normal DMPK RNA.

By disrupting these structures of the pathogenic DMPK RNA, trapped MBNL1 protein is released, allowing it to resume its normal role in RNA splicing. This combination of broad tissue delivery and correction of mis-splicing is the core rationale for PGN-EDODM1. The results we are presenting today provide important clinical evidence of how that rationale is translating into potential impact for individuals living with DM1. Here you see the design of FREEDOM2, our phase II multiple ascending dose study. The study includes three dose cohorts. Each cohort enrolls eight participants randomized three to one to receive PGN-EDODM1 or placebo. Participants receive four doses administered every four weeks over a 12-week period. Today, we will take you through the results from the 10 mg/kg dose cohort. Here are the baseline characteristics of the study.

As you can see, participants were fairly well-balanced, most important in terms of baseline splicing index and CTG repeat number. Our findings to date continue to support a favorable safety profile. PGN-EDODM1 was generally well tolerated across the five and 10 mg/kg cohorts. All participants completed all doses, and all adverse events were mild or moderate in severity. Importantly, there were no serious or severe adverse events, adverse events of special interest, dose-limiting toxicities, or discontinuation. We will discuss kidney function biomarkers on the next slide, but we saw no notable changes in liver or hematologic values and no cardiovascular events. We also saw no anti-drug antibodies. Here's a closer look at certain renal biomarkers and related laboratory measures collected during the study. There were four renal treatment-emergent adverse events, all of which were mild.

At 10 mg/kg, we observed a transient increase in urine albumin-to-creatinine ratio, or UACR, following the first dose. Mean UACR returned toward baseline, and the magnitude of the increase diminished with subsequent dosing. There were no meaningful changes in the eGFR. Mean serum creatinine levels remained within normal range. We observed one participant with a single creatinine value with above-normal measurement. It resolved in 24 hours and is considered clinically insignificant by a consulting nephrologist. Separately, a different participant at 10 mg/kg had one magnesium reading below normal. No intervention occurred. Overall, these findings support the favorable renal safety profile to date. Now turning to biological activity. We are extremely encouraged by the magnitude of splicing correction observed at 10 mg/kg. As you can see from the right-hand panel, following four doses, PGN-EDODM1 produced a 46.5% mean improvement in splicing.

This was measured using the industry standard 22-transcript panel. Let me reiterate again, based on reported clinical data, this is the highest mean splicing correction reported to date in a multiple-dose DM1 study, and we believe it provides evidence of target engagement. It also builds on the dose response observed in FREEDOM, our single ascending dose study. With repeat dosing in FREEDOM2, we have seen a significant step up in splicing correction between five and 10 mg/kg. We believe the magnitude of this effect is especially compelling. On the next slide, you can see that it was supported by a meaningful level of consistency across participants. Four of the six participants at 10 mg/kg achieved splicing improvement greater than 50%, with individual improvements ranging up to 77%.

This has been particularly notable in the context of natural history data showing that approximately 11% of individuals in a DM1 natural history study demonstrated greater than 20% splicing improvement over a two to three-month period, as opposed to the 83% of individuals in the 10 mg/kg arm of FREEDOM2. This reinforces that the compelling improvement in mean splicing was not driven by a few participants, further strengthening the evidence of robust target engagement with PGN-EDODM1. Turning to muscle exposure. Following four doses of PGN-EDODM1, we observed increasing concentration in tibialis anterior muscle. In FREEDOM2, mean tissue concentration reached 150 ng/g at five mg/kg, and increased to 222 ng/g at 10 mg/kg, measured seven days after the fourth dose. The single dose results from FREEDOM are included for context and were measured 28 days after dosing.

Now, I'll hand the presentation to Dr. Johanna Hamel, Associate Professor of Neurology, Pathology, and Laboratory Medicine at the University of Rochester, who will review our functional outcome results. Dr. Hamel?

Johanna Hamel
Associate Professor of Neurology, Pathology, and Laboratory Medicine, University of Rochester

Thank you, Paul. I'm pleased to join you today. As Paul mentioned, I'm an Associate Professor of Neurology, Pathology, and Laboratory Medicine at the University of Rochester, where I care for patients with acquired and hereditary neuromuscular diseases, but with particular expertise and focus in DM1. I also served as an investigator in the FREEDOM-DM1 clinical study. I believe the molecular findings Paul has just presented are especially compelling, and I'll now walk you through the key functional outcomes from the 10 mg/kg cohort. To put these functional results in context, DM1 is a multi-systemic disease with a variable presentation in patients. Muscle weakness, myotonia, and limitations in balance and mobility are most common, most conspicuous, and can affect independence and daily activities. The assessments I'll review examine different dimensions of muscle function, including myotonia, hand grip strength, balance, and mobility.

I'll begin with video hand opening time, or vHOT, an objective measure of myotonia. It assesses how quickly a participant can open the hand following contraction, with a shorter time indicating improvement. Myotonia measurements can vary over time in a patient based on the biologic variability of this symptom. At 10 mg/kg, improvement was evident at the first post-baseline assessment at week four and was maintained through week 16. The mean improvement was 4.3 seconds at week 13 and 3.9 seconds at week 16, representing an approximately 53% improvement from baseline in vHOT. The pooled placebo group remained close to baseline. The magnitude, rapid onset, and persistence of this change are highly encouraging. Turning to the association between splicing correction and myotonia. CLCN1 encodes a skeletal muscle chloride channel that is essential for normal skeletal muscle relaxation.

Its mis-splicing is believed to be a primary driver of myotonia in DM1. Here you see CLCN1 splicing correction plotted on the X-axis and vHOT plotted on the Y-axis. Improvement is indicated by the blue arrows. To examine this, the change in CLCN1 splicing at a group level was plotted against the change in vHOT time. In gray, you see the placebo, which demonstrated a 4.6 point improvement compared to baseline in the CLCN1 differential splicing index, or DSI, and a corresponding 0.6 second worsening in vHOT time. In teal, down below, in the 10 mg/kg cohort, you see a 33.2 point improvement in the CLCN1 DSI and a corresponding 4.3 second improvement in vHOT time at 13 weeks. The error bars indicate the standard error of the mean. These cohort level data are consistent with a dose-dependent improvement between correction of mis-splicing and an observable functional outcome.

The study also evaluated hand grip strength, an objective measure of muscle strength relevant to many daily activities. At 10 mg/kg, improvement in hand grip strength was observed at week eight and was maintained through week 16. Hand grip strength improved by 16% at week 16, with a maximum percent predicted normal, or PPN, that improved by 6.3 points. Hand grip strength increased 5.3 points above baseline at week 13. Placebo improved by 0.9 points at week 16. Hand grip strength is often a symptom that presents early in the disease, and seeing this improvement supports the ability of EDODM1 to reach and restore function in distal muscles critical to the patient. Timed Up and Go, or TUG, is a measure of transitional mobility and balance. Participants stand up from a chair, walk 3 meters, turn around, return to the chair, and sit back down.

At 10 mg/kg, TUG improved by 0.6 seconds at week 13, and that improvement was maintained at week 16. By comparison, the pooled placebo group was unchanged at week 13 and worsened by 0.5 seconds at week 16. Seeing a sustained impact on TUG, culminating a greater than one-second change in TUG at week 16 compared to placebo, is encouraging. The TUG measurement is a key measurement that captures several impacted functional aspects in this disease. The 10 m walk/run test provides a measure of mobility that determines the time required to cover 10 m. The 10 mg/kg EDODM1 cohort improved 10 m walk/run times from baseline at all time points assessed, including by 0.6 seconds at week 13 and 0.4 seconds at week 16, a 6.8% improvement. The pooled placebo group of four patients showed considerable variability.

These results are directionally favorable and contribute to the broader pattern of improvement observed across multiple measures of function. Taken together, these key functional outcomes at 10 mg/kg are highly encouraging, as they show improvements across clinically relevant measures, including myotonia, mobility, balance, and grip strength. With that, I'll turn the call back to James.

James McArthur
President and CEO, PepGen

Thank you, Dr. Hamel. As I said at the top of the call, we are very excited and encouraged by these data. The robust 46.5% splicing correction observed was accompanied by improvement across multiple key functional measures. At 16 weeks, the myotonia was reduced 52.7% as measured by vHOT, and accompanied by a 16.2% improvement in hand grip strength, an 8.5% improvement in Timed Up and Go, and a 6.8% improvement in the 10-meter walk/run test. These results span both proximal and distal muscles impacted by DM1 that affect mobility, myotonia, balance, and strength. We also observed favorable safety findings with no serious adverse events, nor dose-limiting treatment-emergent adverse events, and no discontinuations. We believe the magnitude of the splicing correction and the highly encouraging trends across multiple functional measures further strengthen our confidence in the potential of PGN-EDODM1 to improve the lives of people living with DM1.

As Paul mentioned earlier, the 12.5 mg / kg cohort of FREEDOM2 is fully enrolled, with all participants having received up to three doses. We expect to report results from cohort three in the first half of 2027. The ongoing FREEDOM2 open-label extension, or OLE, is designed to evaluate the long-term safety, tolerability, and clinical impact of PGN-EDODM1 beyond the initial treatment period. 19 patients are enrolled to date in this study, and we have delivered 100 doses at five mg/kg and over 35 doses at 10 mg / kg. We expect to report additional clinical data from participants originally treated at 5 mg / kg, along with the longer-term safety data at 10 mg/kg, in January of 2027.

Additionally, we plan to initiate an expansion cohort running in parallel to cohort three to generate longer-term, up to nine months of data, with PGN-EDODM1 in additional participants. In closing, we are very confident in PGN-EDODM1's potential to deliver meaningful benefit to the DM1 community. With that, we are happy to take any questions. Operator?

Operator

Thank you. As a reminder, if you would like to ask a question, please press star one one on your telephone and wait for your name to be announced. To withdraw your question, press star one one again. Due to time restraints, we ask that you please limit yourself to one question and one follow-up question. Please stand by while we compile the Q&A roster. Our first question will come from the line of Joe Schwartz with Leerink Partners. Your line is open.

Joe Schwartz
Analyst, Leerink Partners

Great, thanks. Congrats on the very strong results. I have one for management and one for Dr. Hamel. James or Paul, are you measuring anything outside of skeletal muscle, given the broad tissue reach that PGN-EDODM1 showed in NHPs? If so, when can we see that data? Dr. Hamel, a related question for you, but beyond muscle, how would you most want to see patients benefit, knowing what troubles them the most, and how does PGN-EDODM1 look like it could address those symptoms based on what you see most in your practice today?

James McArthur
President and CEO, PepGen

Thanks, Joe, for your question. Let me kick that one off. You're correct. We have observed broad distribution of oligonucleotides to a variety of tissues that are impacted in patients, beyond skeletal muscle. This includes the GI tract, the heart, the diaphragm, and so forth. At three months, however, we would not be reasonable to expect to see movement in some of these outcome measures that must be measured by things such as MDHI or other outcome measures, such as looking at forced vital capacity and so forth. This will take longer-term studies, and we are continuing to monitor this in ongoing studies, including the open-label extension work that we're doing today.

We look forward to reporting those data out in the future, and we imagine we will see a profound impact, as we have seen today across a broad range of skeletal muscles with the data we've reported today in these future assessments. With that, I'll turn it over to Dr. Hamel.

Johanna Hamel
Associate Professor of Neurology, Pathology, and Laboratory Medicine, University of Rochester

Yeah. Thank you for the question. As a clinician, this is a very important question. However, skeletal muscle involvement, as I said, is really the most conspicuous, and oftentimes in patient-reported outcome studies, is really at the top in terms of impact on people's lives. However, very important non-skeletal muscle involvement includes gastrointestinal symptoms, swallowing, GI dysmotility, bowel urgency, et cetera, as well as the CNS manifestations, so excessive daytime sleepiness, sleep apnea, et cetera. Those are incredibly important to patients and clinicians alike, and it is too early at three months to see any signals in those domains. I, as a clinician, explore that when I see my study participants. However, to really pick up a signal there, I'm very excited to see future data from the FREEDOM program, and I'm interested to see the effects on those domains as well.

Typically, I would expect a smooth muscle signal and potentially the CNS effect, so I am very excited to look at that in the future.

Joe Schwartz
Analyst, Leerink Partners

Very helpful. Thank you.

Operator

One moment for our next question. That will come from the line of Paul Matteis with Stifel. Your line is open.

Speaker 7

Hi there. This is Matthew on for Paul. Thank you so much for taking the question, and congrats on the strong data. Maybe a clarifying one for us. For the four mild renal AEs, are these all related to the transient albuminuria, and what do you think is the mechanism driving this? As a quick follow-up, based on your modeling, how much more exposure or efficacy are you expecting with the 12.5 mg/kg versus the 10 mg/kg? What should we expect there? Thank you so much.

James McArthur
President and CEO, PepGen

Perhaps I could take the modeling question and mechanism question, and then Dr. Streck will address the specifics of the four renal AEs. From a modeling standpoint, while we were not seeing, as we went from five to 10 mg/kg, a dose-proportional increase in muscle concentration, as Dr. Streck pointed out, you must understand that when we're looking at muscle concentrations, we're looking at the totality of oligo associated with the muscle. This includes oligo on the outside of muscle, on the inside, but stuck in parts of the cell that are not productive, and then, of course, oligo that is present in the nucleus. It's only that oligo in the nucleus that is going to be functionally relevant. So, we may still see, at 12.5, some meaningful increase in terms of the impact on splicing and functional outcomes.

That said, we're just extremely thrilled with the data that we've produced today at 10 mg/kg, clearly a dose that has profound impact both on splicing as well as functional outcomes, and which we would see based on this activity data and its safety profile as a dose that we could take forward in future clinical studies. In terms of the mechanistic underpinning of the renal signals and why we see these transient increases in renal signals, we do not yet know the mechanistic underpinnings. Preclinical pharmacology work is going on to explore this further. However, as Dr. Streck pointed out, all of these were mild in nature and transient. With that, Dr. Streck can tell you what the four mild renal AEs were.

Paul Streck
EVP and Head of Research and Development, PepGen

Yeah, Matthew, as James mentioned, they were all minor, and they were all related to the changes that we saw in the urine albumin. So there were two related to the urine albumin, one proteinuria, and one that was classified as general renal disorder, again, all being mild. So, again, certainly nothing traveling with any of the measures that we discussed or concern for any sort of a signal that we are observing.

Speaker 7

All right, thank you. That's super helpful. And congrats again on the data.

Paul Streck
EVP and Head of Research and Development, PepGen

Thank you.

Operator

One moment for our next question. That will come from the line of Debjit Chattopadhyay with Guggenheim. Your line is open.

Debjit Chattopadhyay
Analyst, Guggenheim

Hey, good morning, and congrats on the data. Long time coming. Good for you guys. I got a couple. One, if I could start with Dr. Hamel. How would you rate these data versus the alternative approaches that are being explored to treat DM1, and is there a specific endpoint you would recommend a sponsor to choose for a registration study?

James McArthur
President and CEO, PepGen

Let me just kick that off, Debjit. We generally are not going to be referring to other folks' data. We're really focused on really the extraordinary results we reported today. But I'd be very happy to have Dr. Hamel speak to endpoints that she thinks could be endpoints that would be appropriate in taking forward and that would be impactful in her view as a practitioner.

Johanna Hamel
Associate Professor of Neurology, Pathology, and Laboratory Medicine, University of Rochester

Yeah, thanks for the question. As a clinician and investigator, I find this data in particular interesting because it really shows effects across important domains, and that includes hand function, but not just myotonia or grip strength, but in fact both impacting hand function as well as mobility. Hand function and mobility are often in the top of the list in terms of patient impact on daily life. Mobility, that is the 10 m walk/run and the TUG. The TUG also measures balance. There are many, many components, and this data shows signals across all those functional outcome measures. I wouldn't like to pick a winner because I think the message here is there are signals across all those domains, plus partnered with really a strong biological footprint in splicing, and this combination is very encouraging.

I hope this puts it in context to the current landscape for you, as from my clinical perspective.

James McArthur
President and CEO, PepGen

Maybe Debjit, I could just follow up. As we've talked many times in the past, this is a disease of mis-splicing, and because of that mis-splicing, you have all of the pathologies that happen downstream. We think the extraordinary results that we've reported today in terms of correction of mis-splicing provides a context in the landscape of other approaches that are being pursued and how one should go and look at this. We're very, very pleased by these results.

Debjit Chattopadhyay
Analyst, Guggenheim

Got it. Given the strength of the splicing data and the vHOT data, and especially the impact on the CLCN1 gene, could you consider using these splicing and vHOT as core primary endpoints for a potential registration study?

James McArthur
President and CEO, PepGen

Very interesting question, Debjit, and I think it's certainly something that we could go and look at. I think with the breadth of the response that we're seeing here today across multiple functional outcome measures, and with the dynamic range which we are looking at changes in splicing as we go from five mg/kg to 10 mg/kg, I think that's certainly a possibility that we could look at this, whereas other approaches with a much smaller impact on splicing might not have had that available to them. It's certainly something we'll consider in our conversations with regulators.

Debjit Chattopadhyay
Analyst, Guggenheim

One last follow-up. Given that the 12.5 mg/kg dose, you've already dosed or treated patients with three doses, do you need to wait for the data from this cohort before committing to what a registration or go-forward dose is likely to be? Or I think you've seen enough with the 10 mg/kg to move that forward.

James McArthur
President and CEO, PepGen

As you suggest, the 10 mg/kg data is extremely strong, and as a standalone dataset, would certainly be something we'd consider taking 10 mg/kg for. We do think the 12.5 mg/kg cohort dataset, however, will be informative. It'll be informative from the standpoint of where we are on the dose curve in terms of dosing and its corresponding increase in splicing correction. If we do see meaningful changes in splicing correction at 12.5, how that then translates into functional outcome measures. But I think as importantly, it'll also tell us more about the safety profile of this drug as we push above the 10 mg/kg dose cohort.

The totality of this data, combined with the open-label extension data, we believe will support an end- of-phase II meeting with regulators and support our designing a pivotal trial design that would allow us to seek the approval of EDODM1 to treat people living with myotonic dystrophy type 1.

Debjit Chattopadhyay
Analyst, Guggenheim

Appreciate it, and congrats again.

James McArthur
President and CEO, PepGen

Thank you.

Operator

One moment for our next question. That will come from the line of Kostas Biliouris with Oppenheimer. Your line is open.

Kostas Biliouris
Analyst, Oppenheimer

Thanks for taking our question, and congrats on the impressive data. A couple of questions from us. The first one, can you talk a little bit about the vHOT baseline in this cohort and whether you required any minimum threshold? Because this vHOT baseline topic has been a key discussion among investors and KOLs, and I have a follow-up. Thank you.

James McArthur
President and CEO, PepGen

I can speak to our vHOT baselines, and then Dr. Hamel can add her thoughts on their potential impact on vHOT and the variability of that outcome measure. We did provide the baseline measurements for all of the outcome measures that we reported today in the slides that we shared with you. As you can see, the baseline measurement for the vHOT for the 10 mg/kg cohort was a little over seven. That is similar to what was reported by another company in their phase II study. I think that could be used as a comparable amount.

This is sort of, as we've talked previously, this is the range in which we're trying to find our vHOT patients with baseline myotonia, because when you look at patients who have much higher baseline measurements, you can see a greater amount of variability of those outcome measures. I think from the standpoint of our data, we're pleased with the baseline measurement here in the active group of seven, and think the vHOT results are very, very robust. Dr. Hamel?

Johanna Hamel
Associate Professor of Neurology, Pathology, and Laboratory Medicine, University of Rochester

Yeah. Thanks for the question. I take that point. You're getting at, well, the baselines could introduce a floor effect or regression to the mean effect, and that could bring out a drug effect that might be exaggerated. Point taken. However, the way I look at it is there are a couple points that really provide or strengthen my confidence in the data. One is that these measurements were really consistent across multiple measuring time points, as well as the linkage to the biological signal, the target engagement signal of splicing, and not just the general splicing 22 panel, but also the root cause, or definitely one of the primary root causes of myotonia, which is the CLCN1 splicing. We have a large body of evidence focused in the literature on CLCN1 and its relationship to clinical myotonia.

Seeing these signals in the data, not just the clinical outcome measure response, but linkages to the molecular markers, plus the consistency across time points really supports my confidence. But of course, point taken, more data is needed, and I'm looking forward to see the additional cohort and more clinical data.

Kostas Biliouris
Analyst, Oppenheimer

Great. Thank you so much. Maybe one follow-up on the correlation between function and splicing. You showed the beautiful correlation between CLCN1 and vHOT. Any other correlations across the 22 genes in the CASI group? Anything between any particular gene and any functional endpoint that you could potentially leverage to select your phase III primary endpoint? Thank you.

James McArthur
President and CEO, PepGen

Yeah, maybe I speak to that, Kostas, that we did see across all 22 genes improvement in the splicing of every one of them in our analysis. We really do need, however, I think, more data, which we'll get from the 12.5 mg/kg, to go and do the sort of analysis that you're indicating. We focused in on CLCN1 initially because it had perhaps the strongest association with a particular functional outcome measure, myotonia. So, a clear association can be made with its movement today. But we look forward in the future when we are unblinded to the data and we can look at individual participants and their responses, both in terms of splicing as well as functional outcomes, and looking at additional correlations.

Kostas Biliouris
Analyst, Oppenheimer

Thank you.

Operator

One moment for our next question. That will come from the line of Ananda Ghosh with H.C. Wainwright. Your line is open.

Ananda Ghosh
Analyst, H.C. Wainwright

Hey. Hi, guys. James and team, congratulations on perhaps the field-defining splicing data. I have a couple of questions. The first one maybe, when you look at the level of splicing and the magnitude of the functional change, especially given the data we are seeing from the landscape, what did the data teach you across the functional endpoints, and specifically with vHOT, which is probably the first endpoint to move in DM1 study? Also, if you can comment on the durability of vHOT and what it tells you as you think of designing a trial with respect to an accelerated approval pathway approach. Thanks.

James McArthur
President and CEO, PepGen

Yeah. If I understand your question correctly, Ananda, in terms of the robustness of the responses we see of these different measures at this point in time, it's an early dataset from the standpoint of looking at three months. We look forward to seeing the longer-term data. What we have seen with other outcome measures is that as we move from three months to six months, you can see several of these outcome measures actually become more pronounced, which makes sense from the biology of this disease. As we restore normal splicing and the corresponding proteins are expressed, we would expect to see the development of new muscle and new functionalities in people living with this disease. And so, we would expect to see that many of these functional outcome measures to improve over time. So, we look forward to seeing that dataset from the open-label extension.

From the standpoint of the robustness of the vHOT measure, I think we're very pleased that we saw very rapidly at four weeks an improvement in vHOT, and it was sustained throughout the entire study. I think with more profound splicing correction, both in terms of the absolute levels, but perhaps more importantly, with deep penetration with five of six individuals showing correction of splicing correction, we can go and see a more robust vHOT response. And it's certainly reflected in this data today.

Ananda Ghosh
Analyst, H.C. Wainwright

Got it. One follow-up question on the CLCN1. When you look at the correlation with your vHOT splicing and the CLCN1 data, how does it correlate with the prior literature analyzing CLCN1 and vHOT?

James McArthur
President and CEO, PepGen

Perhaps I could start off, and then Dr. Hamel could add her thoughts to it. In the literature, and this is natural history data, it is suggested that you can lose a significant portion of CLCN1 splicing, perhaps 70% or so, before one begins to start seeing a meaningful impact on myotonia. This is perhaps why vHOT moves very early on, and it moves in response to relatively small splicing correction. I think that is the biology in the literature today. I think the really pronounced effect we see on vHOT with over four seconds of improvement is perhaps reflective of the deep splicing correction, both in terms of absolute level as well as the number of patients responding. Perhaps I could ask Dr. Hamel her thoughts.

Johanna Hamel
Associate Professor of Neurology, Pathology, and Laboratory Medicine, University of Rochester

Yeah. In some of the studies we have done in Rochester, we looked at this, and it seems like that you have to hit a certain threshold to make a dent in treating myotonia and really correct CLCN1 to a certain degree, and then you see, at least based on correlation association studies, and see a response in the clinical measure. This data just tells me that the drug is hitting that threshold and making it over the hump and can restore myotonia. Yeah, so that is encouraging and consistent with what we know from natural history studies.

Ananda Ghosh
Analyst, H.C. Wainwright

Great. Thanks. Maybe one last question. When do we get to see the eGFR change data and magnitude of albuminuria data?

James McArthur
President and CEO, PepGen

I am sorry, could you repeat that question again? I missed the first bit.

Ananda Ghosh
Analyst, H.C. Wainwright

Yeah. James, when do we see some color on the eGFR data, if there is any, and albuminuria data, like in the coming months, or what's the plan with some of those details of the 50 data analysis?

James McArthur
President and CEO, PepGen

I'll ask Dr. Streck to comment on this.

Paul Streck
EVP and Head of Research and Development, PepGen

Yeah. In terms of the albuminuria, in discussion with the nephrologist, we know that a level of albuminuria of 1,000 is typically consistent with podocyte damage. We had no levels of albuminuria that reached that level. This increase in the UACR did not correlate with other kidney biomarkers we discussed today, so we feel relatively confident that this is not something that is being hidden among other measures such as GFR, other things. We feel it's an isolated thing that's going on within the glomeruli, potentially change of permeability, but we need to really explore that more. But again, no concerns in terms of any cellular damage that's going on, and no cumulative effects of this.

Ananda Ghosh
Analyst, H.C. Wainwright

Great. Thanks very much, guys, and congrats.

Paul Streck
EVP and Head of Research and Development, PepGen

Thank you.

Operator

One moment for our next question. That will come from the line of Tazeen Ahmad with Bank of America. Your line is open.

Speaker 11

Hi, good morning. This is Wesley on for Tazeen. Congrats on the data this morning. I had a question on the parallel expansion cohort you plan to run. Can you give a little more color on what you expect to see there, what dose you're planning to use for these patients? Is this separate from what you're seeing in the OLE and how this is informing discussions with FDA as you're moving forward for activating the trials here in the U.S.? Thank you.

James McArthur
President and CEO, PepGen

Thanks for the question. At this point in time, the FREEDOM2 study is closed to new patients as we fully enroll the cohorts one through three. We have a large number of sites and patients really engaged with this study, and we wanted to be able to enroll them and get additional data for this program. This protocol with the expansion cohort is not yet approved, so it's still being reviewed by regulators. But we would seek to enroll additional patients for up to a nine-month period of time, and the dose is likely to be 10 mg/kg based on this very robust data set today.

From our standpoint, the FREEDOM2 study and the open-label extension will drive our discussions with regulators and the design of the pivotal study, and the expansion cohort will just continue to add data to the database and be useful for long-term discussions.

Speaker 11

Okay. Thank you very much. Congrats again.

James McArthur
President and CEO, PepGen

Thank you.

Operator

One moment for our next question. That will come from the line of Laura Chico with Wedbush. Your line is open.

Laura Chico
Analyst, Wedbush

Hey, good morning. Thanks very much for taking the question. James, I realize this might still require more data from future studies, but any insights into the durability of responses beyond week 16? I guess I'm curious to understand how long the effects are maintained if a Q4 week interval is actually. Could that be extended? Related to that, I'm wondering, could you perhaps contrast the renal safety profile of what you're observing with EDODM1 versus what was previously observed with PGN-EDO51? I guess realizing these are different patient populations, but any distinctions on the albuminuria changes that you're observing in DM1 versus DMD? Thanks.

James McArthur
President and CEO, PepGen

Thanks, Laura. In terms of the four-week dosing regimen that we've employed, this is supported by preclinical biology. As you can see from these really extraordinary, robust responses that we're seeing today, we think it certainly seems to be working from the standpoint of improving splicing and resulting in profound movement and functional outcome measures. We currently have no plans to go and explore an alternative dosing regimen. I'll speak at a high level about the difference between the two programs, and then Dr. Streck can speak to the albuminuria that was observed here versus anything observed in the DM1 program.

We have seen consistently the two molecules, PGN-EDO51 and EDODM1, behave very differently, both in terms of non-human primate data as well as in patients, in terms of both the level at which we began to see movement of any kidney biomarkers, and then the magnitude of the movement of those biomarkers, even at those dose levels. We have always seen with EDODM1 that it has been well tolerated across this dose range, and that the movements that we've seen in terms of any kidney biomarkers have been transient in nature and far less pronounced. We're very pleased that this data has continued to pan out in this way as we've advanced through clinical development in patients. Dr. Streck?

Paul Streck
EVP and Head of Research and Development, PepGen

Yeah, and to add on that, I suppose if we look at the open-label extension trial, I'm very comforted by the fact that we're essentially seeing very few, if any, dropouts in that trial, which is usually an indication that patients aren't going to stay in that unless they're seeing any severe AEs or they don't feel as though they're getting some kind of benefit from it. So, in terms of the durability of response, we'll have more data for you as we look at the open-label extension trial throughout next year. But again, like I say, from a physiologic perspective, no real reason to believe that splicing should change over time. In fact, while we're not measuring it by a biopsy, we'd like to think that that level is maintained and functional gets better over time. But obviously, more to come with that.

Laura Chico
Analyst, Wedbush

Thank you.

Paul Streck
EVP and Head of Research and Development, PepGen

In terms of comparing, I'm sorry.

Operator

Go ahead, sir.

Paul Streck
EVP and Head of Research and Development, PepGen

Okay, sorry. In terms of comparing DM1 to DMD, I think it's a very different picture from a renal perspective. With the DMD program, we certainly saw movements in creatinine as well as eGFR that are a less sensitive measure. So when they're moving, obviously there's some meaningful things going on. Additionally, those measures took anywhere, usually somewhere around 21 days to resolve. We are consistently seeing resolution of the urine albumin decrease between day three and day seven, with no movement in eGFR, no movement in creatinine. So we really feel like we have a very different renal picture here between the DMD and DM1 program. Not to mention the increasingly improving albuminuria that occurs with increasing doses. So, we continue to monitor it, but do think we're seeing a very different kind of scenario between the two molecules.

Operator

Thank you. One moment for our next question. That will come from the line of Adam Vogel with Craig-Hallum. Your line is open.

Adam Vogel
Analyst, Craig-Hallum

Great. Thank you. Hey, team. Congratulations on today's data. Wonderful to see. Just one, I guess, on the FDA hold and developmental timing. Has the FDA agreed that the mouse study package underway will be sufficient to address the hold, or is the scope of that additional work still being defined? Which remaining decisions remain that could impact that second half of next year into phase II timing? I just have a quick follow-up for Dr. Hamel.

James McArthur
President and CEO, PepGen

Sure. I will address the hold question, Adam. Just to remind everyone, we have an open IND in the U.S. The partial clinical hold is with respect to the multiple ascending dose study. As I have highlighted before, the hold focuses in on a study that was submitted several years ago, the subchronic toxicology study in mice, and questions that the FDA raised in terms of some of the biology that we saw in mice in that study. We are doing and continue to do mouse studies that we believe will ultimately allow us to address the questions of FDA, and we look forward to sending these results along with the additional clinical results that we have communicated today along to FDA to resolve this.

I should mention that all the data that FDA has in its possession has also been shared with Canadian, U.K., South Korean, Australian, and New Zealand health authorities, where this study is open and proceeding. We do believe that we will be able to address the questions from FDA around this mouse toxicology question over time, and it is not currently impacting our ability to execute on and conduct this study. What was your follow-on question, Adam?

Adam Vogel
Analyst, Craig-Hallum

Yeah, for Dr. Hamel. Just on the patient relevance, I guess, we'd love to hear how you interpret the gap between the functional changes and inconclusive patient-reported outcomes here. I guess, what evidence do you see best distinguishes this as a delayed patient-perceived benefit here?

Johanna Hamel
Associate Professor of Neurology, Pathology, and Laboratory Medicine, University of Rochester

Yeah. Thanks for the question. I think gaps, first of all, I would say that patient-reported outcomes used in this study are very broad. As you may know, the MDHI covers a lot of questions, and some of them include social communication, social interactions. Things like that are at three months, I personally, as a clinician, am not too worried to not see a strong signal there, because I believe that it might take more time and more participants to really see a signal, and boost the participant numbers to see a signal. Now, the other thing I would like to point out is that we all know the placebo effect and being in a trial can be a positive experience. If you see a positive trend in the placebo group as well, that obviously dilutes a treatment group effect.

To really tease that out in the PROs, we just need a longer time period and more participants to really expect that. Now, as a clinician, and having had exposure firsthand to participants, and having many conversations in those trials, I'm not too worried about that. I think DM1 patients are good at answering questions. We have PROs that are disease-specific and have shown signals before. I'm pretty confident that we'll see a signal there in the future, based on the promising target engagement and initial functional outcome data presented today.

Adam Vogel
Analyst, Craig-Hallum

Great. Thank you.

Operator

Thank you. I am showing no further questions in the queue at this time. I would now like to turn the call back over to Mr. McArthur for any closing remarks.

James McArthur
President and CEO, PepGen

Thank you, everyone, for joining our call today. We would also like to thank all the participants and investigators who have been involved in our ongoing studies, as well as the PepGen team. We very much look forward to updating you on our future progress. Thank you, everyone.

Operator

This concludes today's program. Thank you all for participating. You may now disconnect.